Mechanism: Dasatinib+Quercetin (D+Q) treatment in female senescent cells, unlike males, activates AKT1 via estrogen signaling, which then drives NF-κB-mediated pro-inflammatory cytokine release. Readout: Readout: This sex-specific pathway leads to increased inflammation (IL-6, IL-1β, TNF-α) and reduced senolytic efficacy in females, while AKT1 inhibition or ERα antagonism can reverse the inflammatory surge.
Hypothesis
Estrogen signaling shifts the PI3K/AKT pathway isoform preference in female cells, converting senolytic Dasatinib+Quercetin (D+Q) from a pro‑clearance signal into a pro‑inflammatory trigger via preferential activation of AKT1 over AKT2, leading to NF‑κB‑mediated cytokine release.
Mechanistic Rationale
- Dasatinib inhibits Src/Bcr‑Abl and also dampens PI3K/AKT signaling; quercetin modulates PI3K activity through its flavonoid structure.[1]
- In male cells, basal AKT2 dominance supports metabolic survival; acute PI3K/AKT inhibition reduces SASP and promotes senescent cell apoptosis.[2]
- Female cells exhibit higher estrogen receptor‑α (ERα) expression, which upon ligand binding recruits p85 subunit of PI3K to the membrane, biasing signaling toward AKT1.[3]
- AKT1 activation stimulates mTORC1 and IKKβ, amplifying NF‑κB transcription of IL‑6, IL‑1β, and TNF‑α, offsetting senolytic clearance and raising inflammatory markers.
- This isoform switch explains the observed sex‑specific rise in CRP and IL‑6 after quercetin monotherapy in women.[2]
Testable Predictions
- In isolated human senescent fibroblasts, D+Q will reduce SA‑β‑gal positivity in male‑derived cells but increase IL‑6 secretion in female‑derived cells unless AKT1 is pharmacologically inhibited.
- Co‑treatment with an AKT1‑selective inhibitor (e.g., MK‑2206 at low dose) will abolish the quercetin‑induced inflammatory surge in female cells without affecting senolytic efficacy in males.
- Estradiol supplementation to male senescent cultures will recapitulate the female inflammatory response to D+Q, an effect blocked by ERα antagonist fulvestrant.
- In vivo, ovariectomized female mice treated with D+Q will show lower plasma IL‑6 compared with intact females, while estradiol replacement restores the increase.
Experimental Design
- Obtain primary dermal fibroblasts from male and female donors (age 60‑80), induce senescence via irradiation.
- Treat groups: vehicle, D+Q, D+Q+AKT1i, D+Q+ERα antagonist, estradiol pretreatment.
- Measure SA‑β‑gal, Annexin V/7‑AAD, secreted cytokines (IL‑6, IL‑1β, TNF‑α) by ELISA, and phospho‑AKT1/AKT2 levels by Western blot.
- Parallel ovariectomized mouse study with serum cytokine profiling and cardiac tissue senescence markers post‑aortic bypass mimic.
Potential Implications
If validated, the hypothesis would mandate sex‑stratified dosing, suggest AKT1 modulation as a rescue strategy for female patients, and reveal a hormonal gatekeeper of senolytic safety—guiding personalized senolytic regimens that avoid unintended inflammation.
Citations
[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC12456441/ [2] https://www.nad.com/news/a-natural-senolytic-supplement-curbs-heart-aging-in-new-clinical-trial [3] https://aging-us.org/2025/04/senolytic-compounds-show-promise-in-targeted-alzheimers-treatments/
Comments
Sign in to comment.